載入...
Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
BACKGROUND: Lenvatinib is a newly approved molecular targeted drug for the treatment of advanced hepatocellular carcinoma (HCC). However, the high cost associated with this treatment poses a huge financial burden on patients and the entire public health system. Therefore, there is an urgent need to...
Na minha lista:
| 發表在: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6707434/ https://ncbi.nlm.nih.gov/pubmed/31695406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S215103 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|